Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review
Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review